Cerus Stock (NASDAQ:CERS), Trade Ideas

Cerus

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.

News

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

BIDU

BRCC

CERS

PERI

TVGN

U.S. stock futures were mixed this morning, with the Dow futures falling by around 10 points on Monday.

Perion Network Cuts Sales Outlook, Joins Range Resources And Other Big Stocks Moving Lower In Monday&#39;s Pre-Market Session

cathie wood bitcoin

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

ETFs

$BTC

ARKK

ARKW

MRNA

PSNL

TWLO

On Wednesday, Cathie Wood-led Ark Invest made a significant move by offloading shares of Block Inc (NYSE:SQ) amidst Bitcoin (CRYPTO: BTC) prices recovering.

Cathie Wood&#39;s Ark Invest Sells Another Tranche Of Block Shares, Even As Bitcoin Price Stages A Recovery

Red blood cells GERN

Biotech

Health Care

General

Cerus reports results from the ReCePI Phase 3 trial for INTERCEPT Red Blood Cells, meeting the primary efficacy endpoint in cardiac surgery patients. The safety profile is also favorable. Expect FDA application in 2025.

Why Blood Components-Focused Cerus Stock Is Rising Tuesday

Cerus Corp

Craig-Hallum initiates coverage on Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) with a Buy rating and announces Price Target of $5.

Price Target

Initiation

Analyst Ratings

Craig-Hallum Initiates Coverage On Cerus with Buy Rating, Announces Price Target of $5

U.S. stock futures were mixed this morning, with the Dow futures falling by around 10 points on Monday.
Shares of Perion Network Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/peri#NASDAQ">PERI</a>) fell sharply in today&rsquo;s pre-market trading after the company <a href="https://www.benzinga.com/quote/PERI">slashed FY24 revenue guidance.</a>
Perion Network said it sees first-quarter revenue of $157 million, versus market estimates of $175.53 million. The company said it now expects FY24 revenue of $590 million to $610 million, versus prior outlook of $860 million to $880 million.
Perion Network shares dipped 37.6% to $13.17 in pre-market trading.
Here are some big stocks recording losses in today&rsquo;s pre-market trading session.
<ul>
<li>BRC Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/brcc#NYSE">BRCC</a>) shares fell 7.8% to $4.38 in pre-market trading after gaining over 5% on Friday.</li>
<li>Range Resources Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rrc#NYSE">RRC</a>) shares declined 7.3% to $32.46 in pre-market trading. Range Resources is expected to release its first quarter 2024 financial results on April 23 after the closing bell.</li>
<li>Cerus Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cers#NASDAQ">CERS</a>) fell 4.9% to $1.78 in pre-market trading. On March 26, Cerus announced the FDA approval of extended shelf life for INTERCEPT platelet processing sets, doubling previous shelf life.</li>
<li>Oil States International, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ois#NYSE">OIS</a>) shares declined 4.5% to $6.15 in pre-market trading after gaining around 4% on Friday.</li>
<li>Tevogen Bio Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tvgn#NASDAQ">TVGN</a>) fell 3.8% to $2.81 in pre-market trading after dipping 14% on Friday.</li>
<li>Rentokil Initial plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rto#NYSE">RTO</a>) climbed 3.8% to $29.04 in pre-market trading.</li>
<li>Baidu, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bidu#NASDAQ">BIDU</a>) fell 3% to $103.30 in pre-market trading.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/04/38136222/investor-sentiment-improves-following-jobs-data-dow-jumps-over-300-points"> Investor Sentiment Improves Following Jobs Data, Dow Jumps Over 300 Points</a>
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

Perion Network Cuts Sales Outlook, Joins Range Resources And Other Big Stocks Moving Lower In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) stock rose 48.6% to $3.27 during Friday's after-market session. The company's market cap stands at $8.2 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) shares increased by 11.96% to $1.31. The market value of their outstanding shares is at $2.1 million. </li>
<li>Etao International Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETAO#NASDAQ">ETAO</a>) stock moved upwards by 11.11% to $2.7. The market value of their outstanding shares is at $13.8 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) shares rose 7.35% to $2.39. The market value of their outstanding shares is at $1.7 million. </li>
<li>Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) stock rose 6.99% to $12.62. The market value of their outstanding shares is at $294.9 million. </li>
<li>Gossamer Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOSS#NASDAQ">GOSS</a>) stock increased by 6.79% to $1.1. The market value of their outstanding shares is at $248.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Elicio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NASDAQ">ELTX</a>) stock declined by 10.3% to $7.94 during Friday's after-market session. The market value of their outstanding shares is at $81.1 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares decreased by 4.9% to $0.02. The market value of their outstanding shares is at $1.1 million. </li>
<li>Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) stock fell 4.82% to $1.78. The market value of their outstanding shares is at $322.6 million. </li>
<li>MediciNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) shares declined by 4.7% to $1.42. The company's market cap stands at $69.6 million. </li>
<li>Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) stock fell 4.63% to $2.06. The market value of their outstanding shares is at $140.4 million. </li>
<li>Stoke Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) stock declined by 4.33% to $12.03. The market value of their outstanding shares is at $623.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADIL

ATNF

ELTX

ETAO

GOSS

LGVN

MNOV

SINT

STOK

12 Health Care Stocks Moving In Friday's After-Market Session

Cerus Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately. This approval extends the set shelf life by six months from the existing six-month shelf life that took effect following a set component change last year. All INTERCEPT Platelet Processing Sets in both customer and Cerus inventories are now eligible for this six-month extension. This shelf-life extension applies to all sizes of INTERCEPT Platelet Processing Sets currently available in the U.S.
"We are pleased with this successful and timely outcome to our regulatory filing with the FDA to re-establish a longer shelf life for INTERCEPT Platelet Processing Sets in the U.S.," said Vivek Jayaraman, Cerus' chief operating officer. "We expect that this extension will provide relief to our customers' and our supply chains and will give customers the flexibility to balance inventory levels with current and future demand while reducing product expiration risk."
The Company is continuing to generate additional data to pursue potential shelf life extension from the FDA beyond 12 months for the INTERCEPT Platelet Processing Sets.

Cerus Corporation Announces FDA Approval Of Extended Shelf Life For INTERCEPT Platelet Processing Sets, Doubling Previous Shelf Life

On Wednesday, Cathie Wood-led Ark Invest made a significant move by offloading shares of Block Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>) amidst Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) prices recovering.
The Block Inc Trade
The sale, worth $3.5 million, was executed through Ark's flagship ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) and ARK Next Generation Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>) with a total of 42,608 shares sold. The value of the trade, calculated from the latest closing price of $81.46. Notably, at the time of writing, Bitcoin traded nearly 6.6% higher at $67,330.71.
Ark has sold Block shares in every trading session of the current week. On Monday, Ark sold Block <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37811799/cathie-wood-led-ark-invest-sheds-shares-of-jack-dorseys-block-and-coinbase-as-bitcoin-ethe">shares worth $8.95 million</a> and on Tuesday, the firm <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37838566/cathie-woods-ark-invest-isnt-done-selling-shares-of-jack-dorsey-led-block-yet-sheds-7-5m-w">sold $7.5 million worth</a>. For the week, including Wednesday&#8217;s sale, the total stands at $19.95 million.
Notably, Wood came to the defense of Block when the short seller Hindenburg issued an adverse report against the company.
Other Key Trades:
Ark Invest bought shares of Cerus Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>). The firm also bought shares of Personalis Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>).
Ark also purchased shares of Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) through its ARKK fund. Shares of Twilio Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) were sold from both the ARKK and ARKW portfolios.
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37766119/whopping-33-8-million-shifted-to-robinhood-and-people-suspect-this-person-could-be-behind-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Whopping $33.8 Million Worth Of Dogecoin Shifted To Robinhood — And People Suspect This Person Could Be Behind It</a>
<div style="font-family: 'Lato', sans-serif">
<div>
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by Benzinga Neuro, Edited by 
 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Shivdeep Dhaliwal</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>
</div>

Cathie Wood's Ark Invest Sells Another Tranche Of Block Shares, Even As Bitcoin Price Stages A Recovery

Tuesday,&nbsp;Cerus Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) announced topline results for the ReCePI Phase 3 trial of pathogen-reduced INTERCEPT Red Blood Cells (INTERCEPT RBCs) transfused to complex&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/03/b37818869/cerus-corporation-announces-positive-topline-results-for-the-phase-3-clinical-trial-of-the-interce" rel="noreferrer noopener">cardiac surgery patients</a>.&nbsp;
The INTERCEPT Blood System for Red Blood Cells is designed to inactivate blood-borne pathogens and donor leukocytes in RBCs intended for transfusion.
The trial met its primary efficacy endpoint, demonstrating non-inferiority for INTERCEPT RBCs compared to conventional RBCs as measured by the incidence of acute kidney injury (AKI) following transfusion of study RBCs.&nbsp;
AKI is a sensitive transfusion efficacy indicator of RBC tissue oxygen delivery.&nbsp;
In transfused subjects, by modified intent to treat (mITT pre-specified primary endpoint population) the incidence of AKI was 29.3% (46/157) for INTERCEPT RBC recipients compared to 28.0% (45/161) for conventional RBC recipients, demonstrating non-inferiority of INTERCEPT RBCs compared to conventional RBCs with an upper limit of the 95% confidence interval of 10.4% compared with a non-inferiority margin of 14.0% (p = 0.001).
The safety endpoint of the proportion of patients with any related treatment-emergent adverse events within 28 days of last transfusion was not significantly different for INTERCEPT RBCs (2.5%) compared to conventional RBCs (0.6%) (p = 0.130).&nbsp;
&#8220;We continue to look forward to completing the RedeS clinical trial, Cerus&#8217; ongoing pivotal Phase 3 clinical trial for INTERCEPT RBCs enrolling a broader patient population requiring RBC transfusion for acute and chronic anemia,&#8221; stated Richard Benjamin, Cerus&#8217; chief medical officer.&nbsp;
Cerus anticipates initiating a modular PMA application to the FDA in the second half of 2025, with the final PMA module submission planned for the second half of 2026 upon the anticipated completion of the RedeS clinical trial.&nbsp;
Price Action: CERS shares are up 3.23% at $1.91 on the last check Tuesday.
Photo by Narupon Promvichai from Pixabay

WIIM

Cerus Corporation shares are trading higher after the company announced its ReCePI Phase 3 trial of INTERCEPT Blood System met its primary efficacy endpoint.

CERS: 64% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/37819016">Cerus Corporation Announces Its ReCePI Phase 3 Trial Of INTERCEPT Blood System Met Its Primary Efficacy Endpoint; Safety Endpoint Of The Proportion Of Patients With Any Related Treatment-Emergent Adverse Events Within 28 Days Of Last Transfusion Was Not Significantly Different For Intercept RBCs</a>
CRNX: 20% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/37815626">Crinetics Pharmaceuticals shares are trading higher after the company&#39;s Phase 3 PATHFNDR-2 trial of paltusotine in acromegaly achieved the primary and all secondary endpoints.</a>
HOTH: 60% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/37819667">Hoth Therapeutics Says HT-ALZ Emerges As A Promising Novel Solution For Combating Neuroinflammation And Cognitive Deficits Associated With Alzheimer&#39;s Disease.</a>

CRNX

HOTH

Market-Moving News for March 19th

Cerus Corporation Shares Resume Trade, Shares Spike Higher

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

Cerus Corporation Announces Its ReCePI Phase 3 Trial Of INTERCEPT Blood System Met Its Primary Efficacy Endpoint; Safety Endpoint Of The Proportion Of Patients With Any Related Treatment-Emergent Adverse Events Within 28 Days Of Last Transfusion Was Not Significantly Different For Intercept RBCs

Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending

On Wednesday, Cathie Wood-led Ark Invest made significant trades involving Coinbase Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) and Pinterest Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>).
The Coinbase Trade
Ark Invest decided to offload a substantial number of shares in Coinbase, despite Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) reaching new all-time highs on the same day.
According to the data, Ark Invest sold a total of 10,995 Coinbase shares through its ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>), ARK Next Generation Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>), and Ark Fintech Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>). The transaction was valued at $2.8 million. For the day, Coinbase shares closed 1.7% lower at $251.73.
This move comes amid a surge in investments into U.S.-based exchange-traded funds (ETFs) associated with Bitcoin, which saw the digital currency soar to a new peak of $73,709 on Wednesday morning. <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37660169/bitcoin-breaks-73-000-mark-reaching-4-new-highs-in-less-than-a-week">Bitcoin&#8217;s surge</a> coincided with a total net inflow into Bitcoin spot ETFs reaching an unprecedented $1.05 billion on March 12.
The Pinterest Trade 
On the other hand, Ark Invest increased its stake in Pinterest, buying a total of 34,653 shares through ARKK and ARKF. The transaction amounted to $1.12 million. Pinterest shares closed 0.8% lower at $34.60 on Wednesday.
 This move comes as Pinterest continues its efforts to <a href="https://www.benzinga.com/news/24/02/37041761/pinterest-gets-googles-help-in-an-amazon-like-partnership-as-it-continues-to-try-to-make-monetizatio">monetize its platform</a>, enlisting the help of Google in a partnership similar to its existing Amazon partnership. Pinterest&#8217;s shares surged 53% last year and rose 9.5% since the beginning of 2024, despite a revenue miss that saw its stock falling about 20% after-hours before recovering.
See Also: <a href="https://www.benzinga.com/markets/equities/24/03/37640186/nvidia-rumble-boeing-intel-tesla-why-these-5-stocks-are-on-investors-radars-today?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">NVDA, RUM, BA, INTC, TSLA: Top 5 Trending Stocks Today</a> 
Other Key Trades:
Ark Invest sold 35,960 shares of UiPath Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) through its ARK Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>). 
Also through ARKG, the firm bought 295,727 shares of Cerus Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>). Ark Invest sold shares of Twilio Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) through multiple funds.
The firm sold shares of Stratasys Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSYS#NASDAQ">SSYS</a>) through two of its ETFs.
Photo via Ark Invest.
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37579395/crypto-community-lost-staggering-104m-in-bitcoin-dogecoin-shiba-inu-phishing-scams-in-2024?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Crypto Community Lost Staggering $104M In Bitcoin, Dogecoin, Shiba Inu Phishing Scams In 2024: Ethereum Users Hit The Hardest</a>
<div style="font-family: 'Lato', sans-serif">
<div>
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by Benzinga Neuro, Edited by 
 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Shivdeep Dhaliwal</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>
</div>

Equities

ARKF

ARKG

COIN

PATH

PINS

SSYS

Cathie Wood's Ark Invest Sells Coinbase Shares As Bitcoin Hits Yet Another All-Time New High, Buys Stock Of This Social Media Company

Stephens &amp; Co. analyst Jacob Johnson reiterates Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) with a Equal-Weight and maintains $2.5 price target.

Reiteration

Stephens & Co. Reiterates Equal-Weight on Cerus, Maintains $2.5 Price Target

Shares of United Natural Foods, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/unfi#NYSE">UNFI</a>) fell sharply during Wednesday&rsquo;s session following <a href="https://www.benzinga.com/quote/UNFI/earnings">second-quarter results.</a>
United Natural Foods posted adjusted earnings of 7 cents per share, compared to market estimates for a loss of 1 cent per share. The company&rsquo;s quarterly sales came in at $7.78 billion, versus expectations of $7.87 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
United Natural Foods named Giorgio Matteo Tarditi as President and Chief Financial Officer.
United Natural Foods shares dipped 15.2% to $12.61 on Wednesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Rail Vision Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvsn#NASDAQ">RVSN</a>) shares jumped 115.2% to $4.24. Rail Vision announced first commercial installation of its AI-driven main line systems in a national railways line.</li>
<li>Aptorum Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apm#NASDAQ">APM</a>) shares climbed 90.1% to $3.1750. Aptorum Group announced an agreement and plan of merger with YOOV Group Holding Ltd and a split-off agreement to separate its legacy business.</li>
<li>NKGen Biotech, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nkgn#NASDAQ">NKGN</a>) gained 46.5% to $1.35.</li>
<li>TRxADE HEALTH, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meds#NASDAQ">MEDS</a>) rose 39.2% to $11.19 after the company announced a special cash dividend of $8 per share.</li>
<li>Airship AI Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aisp#NASDAQ">AISP</a>) shares climbed 37.8% to $6.82. Airship AI Holdings shares jumped 200% on Tuesday after the company announced that it has been awarded a contract with the Department of Justice for its Acropolis Enterprise Sensor Management video and data management platform.</li>
<li>Enviva Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/eva#NYSE">EVA</a>) rose 33% to $0.9854 after gaining 42% on Tuesday.</li>
<li>American Public Education, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apei#NASDAQ">APEI</a>) gained 31.8% to $14.99 following upbeat quarterly results.</li>
<li>Dada Nexus Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dada#NASDAQ">DADA</a>) climbed 30.6% to $2.5740. Dada Nexus said certain revenues and associated costs were overstated in past financial statements.</li>
<li>Cemtrex, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cetx#NASDAQ">CETX</a>) gained 30% to $4.4361. Cemtrex announced beta release of pioneering AI gun detection feature.</li>
<li>Wave Life Sciences Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wve#NYSE">WVE</a>) gained 28.5% to $6.16 following upbeat quarterly results.</li>
<li>Vincerx Pharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vinc#NASDAQ">VINC</a>) shares gained 24.5% to $6.89. Vincerx will present three posters at the American Association for Cancer Research (AACR) Annual Meeting 2024.</li>
<li>XORTX Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xrtx#NASDAQ">XRTX</a>) rose 24.2% to $5.85.</li>
<li>CareMax, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmax#NASDAQ">CMAX</a>) gained 23.8% to $14.72.</li>
<li>Lantern Pharma Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ltrn#NASDAQ">LTRN</a>) gained 22.6% to $5.90.</li>
<li>Energem Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/encp#NASDAQ">ENCP</a>) rose 22.4% to $8.31. Energem&rsquo;s merger partner recently said it accelerated the timeline for its planned manufacturing plant in Malaysia.</li>
<li>Cerus Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cers#NASDAQ">CERS</a>) gained 22.4% to $2.4350 after the company reported better-than-expected fourth-quarter GAAP EPS results.</li>
<li>Infobird Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ifbd#NASDAQ">IFBD</a>) jumped 22.4% to $6.40.</li>
<li>Genprex, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gnpx#NASDAQ">GNPX</a>) rose 22.1% to $5.03.</li>
<li>BeyondSpring Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bysi#NASDAQ">BYSI</a>) gained 21% to $3.5098.</li>
<li>Crexendo, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cxdo#NASDAQ">CXDO</a>) surged 20% to $6.43 following upbeat quarterly results.</li>
<li>CrowdStrike Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crwd#NASDAQ">CRWD</a>) shares gained 17.2% to $348.73 after the company reported better-than-expected fourth-quarter earnings and revenues and issued upbeat guidance for FY25.</li>
<li>Fulcrum Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fulc#NASDAQ">FULC</a>) rose 17.2% to $12.85.</li>
<li>JD.com, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jd#NASDAQ">JD</a>) gained 17% to $25.08 after the company reported fourth-quarter results above estimates, a new buyback approval and annual cash dividend.</li>
<li>Hippo Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hipo#NASDAQ">HIPO</a>) rose 14.6% to $16.58 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Root, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/root#NASDAQ">ROOT</a>) rose 13.7% to $44.46.</li>
<li>Super Group (SGHC) Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sghc#NYSE">SGHC</a>) surged 10.1% to $3.4350 following fourth-quarter results.</li>
<li>Infinera Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/infn#NASDAQ">INFN</a>) gained 10% to $5.66. Infinera announced availability of next generation multi-haul optical line system functionality for industry-leading GX series platform.</li>
<li>MicroStrategy Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mstr#NASDAQ">MSTR</a>) gained 10% to $1,156.87. MicroStrategy shares fell over 21% on Tuesday after the company announced a proposed private offering of $600 million of convertible senior notes.</li>
<li>Lyft, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lyft#NASDAQ">LYFT</a>) gained 9.4% to $18.45.</li>
<li>Couchbase, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/base#NASDAQ">BASE</a>) shares rose 9.2% to $29.37 after the company reported upbeat fourth-quarter sales and issued upbeat revenue guidance for the first quarter.</li>
<li>NIO Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nio#NYSE">NIO</a>) gained 5.9% to $5.80. On Tuesday, NIO reported fourth-quarter revenue of 17.10 billion yuan ($2.41 billion), up by 6.5% year-over-year and down by 10.3% from the previous quarter.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Entravision Communications Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/evc#NYSE">EVC</a>) shares fell 51.1% to $1.7450 after the company received communication from Meta indicating its intention to wind down its ASP program globally, ending its relationship with all ASPs, including Entravision, by July 1. The ASP program represented a large portion of Entravision&#39;s total consolidated revenue.</li>
<li>Neptune Wellness Solutions Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nept#NASDAQ">NEPT</a>) fell 46.4% to $0.20. Neptune announced decision of Nasdaq Hearings Panel to delist common shares.</li>
<li>bioAffinity Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/biaf#NASDAQ">BIAF</a>) fell 45% to $1.6499 after the company announced pricing of a $2.5 million registered direct offering and a concurrent private placement.</li>
<li>Ocean Biomedical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocea#NASDAQ">OCEA</a>) fell 30.5% to $3.6550</li>
<li>Heart Test Laboratories, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hscs#NASDAQ">HSCS</a>) fell 29% to $0.1272. HeartSciences announced Canada patent grant covering MyoVista Wavelet Technology.</li>
<li>Jaguar Health, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jagx#NASDAQ">JAGX</a>) shares fell 26.7% to $0.0924 after dipping around 12% on Tuesday.</li>
<li>Sunshine Biopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sbfm#NASDAQ">SBFM</a>) dipped 25.8% to $0.0620.</li>
<li>Affimed N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/afmd#NASDAQ">AFMD</a>) fell 22.3% to $0.52 after the company announced a 1-for-10 reverse stock split.</li>
<li>Phunware, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/phun#NASDAQ">PHUN</a>) shares fell 21.8% to $11.49. Phunware shares jumped over 18% on Tuesday amid volatility in Trump-related stocks after Donald Trump won the North Dakota Caucus.</li>
<li>PureCycle Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pct#NASDAQ">PCT</a>) dipped 16.7% to $4.71 as the company announced a corporate update for the fourth quarter and fiscal year ending Dec. 31, 2023.</li>
<li>Nordstrom, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jwn#NYSE">JWN</a>) declined 14.6% to $17.83 after the company issued soft FY24 EPS guidance.</li>
<li>Momentus Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mnts#NASDAQ">MNTS</a>) shares fell 13.2% to $0.6510. Momentus recently received a flight and payload integration services contract from NASA. In another development, Momentus entered into a securities purchase agreement with a single U.S. institutional investor for the purchase and sale of 4.62 million shares of common stock at a purchase price of $0.865 per share and warrant pursuant to a registered direct offering, resulting in total gross proceeds of approximately $4.0 million.</li>
<li>Grifols, S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grfs#NASDAQ">GRFS</a>) fell 13.1% to $5.36 after declining around 7% on Tuesday.</li>
<li>THOR Industries, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tho#NYSE">THO</a>) dipped 11.4% to $112.19 after the company reported a year-over-year decrease in second-quarter financial results and cut FY24 guidance below estimates.</li>
<li>TTEC Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ttec#NASDAQ">TTEC</a>) fell 10.2% to $11.16 after Canaccord Genuity downgraded the stock from Buy to Hold and lowered its price target from $30 to $13.</li>
<li>Dave Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dave#NASDAQ">DAVE</a>) fell 10% to $32.40. On Tuesday, Dave reported a year-over-year increase in fourth-quarter revenue results.</li>
<li>Brown-Forman Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bf-b#NYSE">BF-B</a>) fell 9.8% to $54.82 after the company reported worse-than-expected third-quarter revenue guidance. Also, the company expects its FY24 organic net sales to be flat.</li>
<li>SOPHiA GENETICS SA (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/soph#NASDAQ">SOPH</a>) shares declined 9.8% to $5.05. Sophia Genetics recently reported worse than expected fourth-quarter earnings and issued 2024 guidance.</li>
<li>Xerox Holdings Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xrx#NASDAQ">XRX</a>) fell 9.6% to $16.99 after the company announced a proposed convertible notes offering.</li>
<li>TAL Education Group (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tal#NYSE">TAL</a>) declined 8.9% to $12.02.</li>
<li>Valley National Bancorp (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vly#NYSE">VLY</a>) dipped 8.5% to $7.20.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37502729/cramer-this-reit-is-a-little-too-dicey-as-for-marathon-digital-own-the-pure"> Cramer: This REIT Is &#39;A Little Too Dicey&#39;; As For Marathon Digital, &#39;Own The Pure&#39;</a>

Intraday Update

AFMD

AISP

APEI

BASE

BF-B

BIAF

BYSI

CETX

CMAX

CRWD

CXDO

DADA

DAVE

ENCP

FULC

GNPX

GRFS

HIPO

HSCS

IFBD

INFN

JAGX

LTRN

LYFT

MEDS

MNTS

MSTR

NEPT

NKGN

OCEA

PHUN

ROOT

RVSN

SBFM

SGHC

SOPH

TTEC

UNFI

VINC

XRTX

Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Cantor Fitzgerald analyst Ross Osborn reiterates Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) with a Overweight and maintains $3 price target.

Cantor Fitzgerald Reiterates Overweight on Cerus, Maintains $3 Price Target

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Wednesday.
Shares of Box, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/box#NYSE">BOX</a>) rose sharply during Wednesday&rsquo;s session after the company reported better-than-expected fourth-quarter EPS and announced a $100 million <a href="https://www.tradingview.com/news/benzinga:46fb7a7e0094b:0-box-stock-is-rising-wednesday-what-s-driving-the-action/">expansion of its stock repurchase program</a>.
Total revenues were up 2% on a year-over-year basis. Billings were up 6% in the fourth quarter, coming in at $379.3 million. The company also issued first-quarter revenue guidance above estimates.
Box shares climbed 7.3% to $29.25 on Wednesday.
Here are some other big stocks recording gains in today&rsquo;s session.
<ul>
<li>TRxADE HEALTH, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meds#NASDAQ">MEDS</a>) shares jumped 39.2% to $11.19 after the company announced a special cash dividend of $8 per share.</li>
<li>American Public Education, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apei#NASDAQ">APEI</a>) rose 31.8% to $14.99 following upbeat quarterly results.</li>
<li>Dada Nexus Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dada#NASDAQ">DADA</a>) jumped 30.6% to $2.5740. Dada Nexus said certain revenues and associated costs were overstated in past financial statements.</li>
<li>Wave Life Sciences Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wve#NYSE">WVE</a>) rose 28.5% to $6.16 following upbeat quarterly results.</li>
<li>CareMax, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmax#NASDAQ">CMAX</a>) jumped 23.8% to $14.72.</li>
<li>Lantern Pharma Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ltrn#NASDAQ">LTRN</a>) climbed 22.6% to $5.90.</li>
<li>Cerus Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cers#NASDAQ">CERS</a>) gained 22.4% to $2.4350 after the company reported better-than-expected fourth-quarter GAAP EPS results.</li>
<li>Crexendo, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cxdo#NASDAQ">CXDO</a>) rose 20% to $6.43 following upbeat quarterly results.</li>
<li>Allient Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alnt#NASDAQ">ALNT</a>) gained 17.4% to $35.23 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>CrowdStrike Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crwd#NASDAQ">CRWD</a>) shares climbed 17.2% to $348.73 after the company reported better-than-expected fourth-quarter earnings and revenues and issued upbeat guidance for FY25.</li>
<li>Fulcrum Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fulc#NASDAQ">FULC</a>) gained 17.2% to $12.85.</li>
<li>JD.com, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jd#NASDAQ">JD</a>) climbed 17% to $25.08 after the company reported fourth-quarter results above estimates, a new buyback approval and annual cash dividend.</li>
<li>Lexeo Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lxeo#NASDAQ">LXEO</a>) rose 14.8% to $15.00.</li>
<li>Hippo Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hipo#NASDAQ">HIPO</a>) gained 14.6% to $16.58 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Root, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/root#NASDAQ">ROOT</a>) climbed 13.7% to $44.46.</li>
<li>HashiCorp, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hcp#NASDAQ">HCP</a>) gained 11.1% to $26.64 following fourth-quarter financial results.</li>
<li>Sibanye Stillwater Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sbsw#NYSE">SBSW</a>) climbed 10.6% to $4.3450.</li>
<li>Mobileye Global Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mbly#NASDAQ">MBLY</a>) gained 10.6% to $27.59.</li>
<li>Super Group (SGHC) Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sghc#NYSE">SGHC</a>) rose 10.1% to $3.4350 following fourth-quarter results.</li>
<li>Infinera Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/infn#NASDAQ">INFN</a>) gained 10% to $5.66. Infinera announced availability of next generation multi-haul optical line system functionality for industry-leading GX series platform.</li>
<li>Palantir Technologies Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pltr#NYSE">PLTR</a>) climbed 10% to $26.19 after the company announced an Army contract. The company also announced customers will showcase their work in Palantir&#39;s AI platform at the AIPCon event on Mar. 7.</li>
<li>CleanSpark, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clsk#NASDAQ">CLSK</a>) rose 10% to $16.86.</li>
<li>MicroStrategy Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mstr#NASDAQ">MSTR</a>) rose 10% to $1,156.87. MicroStrategy shares fell over 21% on Tuesday after the company announced a proposed private offering of $600 million of convertible senior notes.</li>
<li>Lyft, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lyft#NASDAQ">LYFT</a>) climbed 9.4% to $18.45.</li>
<li>Couchbase, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/base#NASDAQ">BASE</a>) shares gained 9.2% to $29.37 after the company reported upbeat fourth-quarter sales and issued upbeat revenue guidance for the first quarter.</li>
<li>Insperity, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nsp#NYSE">NSP</a>) rose 8.4% to $103.06.</li>
<li>Hewlett Packard Enterprise Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hpe#NYSE">HPE</a>) gained 7.9% to $19.53.</li>
<li>AeroVironment, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avav#NASDAQ">AVAV</a>) rose 7.7% to $179.96.</li>
<li>Bilibili Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bili#NASDAQ">BILI</a>) gained 7.4% to $10.91.</li>
<li>NIO Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nio#NYSE">NIO</a>) rose 5.9% to $5.80. On Tuesday, NIO reported fourth-quarter revenue of 17.10 billion yuan ($2.41 billion), up by 6.5% year-over-year and down by 10.3% from the previous quarter.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37510405/bitcoin-falls-below-this-key-level-shiba-inu-ecash-among-top-losers"> Bitcoin Falls Below This Key Level; Shiba Inu, eCash Among Top Losers </a>

ALNT

AVAV

BILI

CLSK

LXEO

MBLY

PLTR

SBSW

Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On Wednesday

Cerus shares are trading higher after the company reported better-than-expected Q4 GAAP EPS results.

Guidance

Cerus Sees FY24 Revenue $172M-$175M Vs $185.871M Est.

<h3>Gainers</h3>
<ul>
<li>NKGen Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) stock increased by 62.4% to $1.4 during Tuesday's after-market session. The company's market cap stands at $30.6 million. </li>
<li>vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) stock moved upwards by 13.17% to $15.55. The company's market cap stands at $32.4 million. </li>
<li>Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) stock increased by 9.09% to $2.16. The company's market cap stands at $391.3 million. The company's, Q4 earnings came out today. </li>
<li>Sophia Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) stock increased by 7.32% to $6.01. The company's market cap stands at $391.4 million. The company's, Q4 earnings came out today. </li>
<li>YS Biopharma Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YS#NASDAQ">YS</a>) stock rose 6.36% to $0.65. The market value of their outstanding shares is at $122.1 million. </li>
<li>Aldeyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALDX#NASDAQ">ALDX</a>) shares increased by 6.1% to $4.17. The company's market cap stands at $245.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Heart Test Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) shares decreased by 22.2% to $0.14 during Tuesday's after-market session. The market value of their outstanding shares is at $8.8 million. </li>
<li>Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) stock decreased by 12.56% to $8.08. The company's market cap stands at $440.9 million. As per the press release, Q4 earnings came out today. </li>
<li>Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) shares declined by 10.39% to $1.64. The company's market cap stands at $209.0 million. </li>
<li>Cara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares decreased by 8.8% to $0.83. The market value of their outstanding shares is at $45.2 million. The company's, Q4 earnings came out yesterday. </li>
<li>CareMax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) stock fell 8.42% to $10.89. The company's market cap stands at $40.7 million. </li>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) shares fell 8.01% to $8.5. The market value of their outstanding shares is at $166.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALDX

CARA

CMPX

Envoy Medical, Inc. - Class A Common Stock

COCH

MRNS

VTVT

12 Health Care Stocks Moving In Tuesday's After-Market Session

Cerus Corporation (CERS) has disclosed a new risk, in the Share Price & Shareholder Rights category. Cerus Corporation faces significant risk due t...

Cerus Corporation's New Share Price & Shareholder Rights Risk – A Cause for Worry?

Analysts have been eager to weigh in on the Healthcare sector with new ratings on iCAD (ICAD – Research Report), Mustang Bio (MBIO – Research Repor...

Analysts Offer Insights on Healthcare Companies: iCAD (ICAD), Mustang Bio (MBIO) and Cerus (CERS)

Overall market sentiment has been down on Cerus Corp (CERS)  stock lately. CERS receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator. Cerus Corp has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on CERS!See Full CERS ReportWhat is Stock Sentiment?Sentim

How Will the Market React to Cerus Corp (CERS) Stock Getting a Bearish Rating

In a report released today, Josh Jennings from TD Cowen maintained a Buy rating on Cerus (CERS – Research Report), with a price target of $5.00. Jo...

Cerus's Strong Q4 Performance and Positive 2024 Outlook Prompt 'Buy' Rating

Cerus' soars on meeting main goal of late stage trial for INTERCEPT RBCs in heart surgery patients

The 55 rating InvestorsObserver gives to Cerus Corp (CERS)  stock puts it near the top of the Medical Devices industry. In addition to scoring higher than 79 percent of stocks in the Medical Devices industry, CERSâ€&#x2122;s 55 overall rating means the stock scores better than 55 percent of all stocks. CERS has an Overall Score of

Is Cerus Corp (CERS) a Winner in the Medical Devices Industry?

Cerus Corp (CERS) is lower by Wednesday morning, with the stock declining -4.41% in pre-market trading to 1.95. CERS's short-term technical score of 25 indicates that the stock has traded less bullishly over the last month than 75% of stocks on the market. In the Medical Devices industry, which ranks 122 out of 146 industr

Cerus Corp (CERS) has fallen 4.41% Wednesday In Premarket Trading

Cerus Corp (CERS) is lower by Thursday morning, with the stock decreasing -2.03% in pre-market trading to 1.93. CERS's short-term technical score of 23 indicates that the stock has traded less bullishly over the last month than 77% of stocks on the market. In the Medical Devices industry, which ranks 119 out of 146 industr

Cerus Corp (CERS) Down 2.03% in Premarket Trading

William Bonello, an analyst from Craig-Hallum, has initiated a new Buy rating on Cerus (CERS). William Bonello has given his Buy rating due to a co...

Cerus Corporation: Strong Buy Rating Amidst Growth and Path to Profitability

Cerus gains as Craig Hallum launches at Buy on return to growth

ICAD

MBIO

Press Releases

Bloodbuy Announces Agreement with Cerus Corporation to Offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex on its Digital Marketplace

Cerus Corporation Announces Third Quarter 2023 Financial Results

Cerus Corporation to Participate in Upcoming Investor Conferences

Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2023 Product Revenue and Provides Business Update

Cerus Corporation to Release Fourth Quarter and Full-Year 2023 Financial Results on March 5, 2024

Cerus Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results

Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients

Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life

Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024